{"id":"NCT00349622","sponsor":"Massachusetts General Hospital","briefTitle":"Clinical Trial Ceftriaxone in Subjects With ALS","officialTitle":"Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2006-07-07","resultsPosted":"2014-04-01","lastUpdate":"2014-04-21"},"enrollment":513,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis","ALS"],"interventions":[{"type":"DRUG","name":"ceftriaxone","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Ceftriaxone","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).","primaryOutcome":{"measure":"Survival","timeFrame":"From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs)","effectByArm":[{"arm":"Ceftriaxone","deltaMin":664,"sd":null},{"arm":"Placebo","deltaMin":581,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":58,"countries":["United States","Canada"]},"refs":{"pmids":["28864675","25297012","23613806"],"seeAlso":["http://www.alsconsortium.org"]},"adverseEventsSummary":{"seriousAny":{"events":276,"n":340},"commonTop":["Diarrhea","Cholelithiasis","Neurology - Other","Catheter Exit Site Reaction","Rash/desquamation"]}}